The Hackett Group, Inc. (NASDAQ: HCKT), an ROI-led AI transformation firm, today announced the winners of its annual Hackett Innovation Awards, recognizing organizations that are using artificial ...

BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response ('DDR”) inhibitors, a category of drugs that work by blocking cancer ...

Jared Holz, health care sector strategist at Mizuho Securities, joins 'Squawk on the Street' to discuss GSK’s plan to acquire Nuvalent for $10.6 billion, his view on Eli Lilly, and more. Got a ...

Nuvalent’s late-stage lung cancer treatments zidesamtinib and neladalkib are expected to launch later this year Business live – latest updates GSK’s new boss, Luke Miels, has struck one of the British ...

Jared Holz, health care sector strategist at Mizuho Securities, joins 'Squawk on the Street' to discuss GSK’s plan to acquire Nuvalent for $10.6 billion, his view on Eli Lilly, and more. Trump unveils ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — GSK said Tuesday it would ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Transaction terms include a $124/share all-cash tender offer, implying a 40% premium to prior close, with expected Q3 2026 closing pending antitrust and customary conditions. Regulatory timelines ...

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy Nuvalent for $10.6 billion in a move that would add two late-stage lung cancer drugs. The UK pharma group is ...

GSK (GSK) reported better-than-expected financials for Q1 2026 on Wednesday as sales from its HIV and cancer medicines offset a sales decline for its general medicines, including its respiratory ...

GSK (GSK) is preparing a high-stakes push into oncology, lining up five late-stage trials at once for a promising cancer drug as new CEO Luke Miels seeks to reshape the company’s historically cautious ...